Academician Jiang Jiandong: Azvudine (treatment of new crown) is very effective

After listening to two reports by Academician Jiang Jiandong, one was held at the "China Pharmacy Development Conference" held by the Chinese Academy of Medical Sciences on February 26-27; On March 17th, on "Exploring the Road to New Drugs in China by Absorbing the Thought of System Theory"
.

In the two reports, Academician Jiang Jiandong, President of the Institute of Materia Medica, Chinese Academy of Medical Sciences, focused on the research and development and progress of Azvudine in the treatment of new crown indications, saying that Azvudine is very effective in treating both mild and severe new crowns
.

Promising anti-coronavirus drug

Academician Jiang Jiandong introduced that the Azvudine treatment team for the new crown is chaired by Real Biology, and the Chinese Academy of Medical Sciences is responsible for pharmacology, efficacy and pharmacokinetic research.
Among them, Academician Wang Chen, president of the Chinese Academy of Medical Sciences, is responsible for clinical research, Beijing Ditan Hospital, Wuhan More than 10 hospitals including Zhongnan Hospital participated
.

In the report, Academician Jiang Jiandong said that in February 2020, Azvudine was found to be able to resist the new coronavirus, and it was approved for Phase III clinical trials in April 2020.
Now the Phase III clinical trials are over.
Look, it's more optimistic
.

The clinical effect of azvudine is as follows.
Generally, the nucleic acid turns negative after 3-4 days of oral administration
.

And it doesn't matter whether the patient has taken any medicine before, or has been taking medicine for a while, he can still use azvudine
.

Azvudine is phosphorylated three times in the thymus

At the cellular level, Azvudine’s antiviral strength is actually not as strong as Remdesivir, four or five times worse than Remdesivir, but the clinical effect is much better than Remdesivir, and it can be taken orally 5mg, Remdesivir Sivir injection is 100mg
.

This brings us to the question that there must be a factor at play that we don't understand
.

For example, Remdesivir adds phosphoric acid on it, but Azvudine does not add phosphoric acid
.

(This picture is a comparison of Remdesivir and Azvudine
.

The thymus gland is very important
.

The answer we found is: Azvudine completes three phosphorylations in the thymus, clears the virus in the thymus, protects the immune system, and the immune system also has an antiviral effect
.

So, I think this medicine is a dual treatment
.

(Other data we have seen show that: after azvudine enters the human body, the distribution is relatively special, and the distribution on the thymus is the largest
.

Azvudine has the problem of treating the symptoms and the root, anti-virus is the “symbol”, and thymus protection is equivalent to the “root”
.

Concord's A+B Plan

In the report, Academician Jiang Jiandong said that for the treatment of the new crown, the Chinese Academy of Medical Sciences proposed the A+B plan, that is, the combination of azvudine and carrimycin, which they originally called the "Concord Plan"
.

Clindamycin is an approved drug that is currently undergoing Phase III clinical trials for the treatment of COVID-19 in the United States, and 26 patients are yet to be enrolled
.

Carrimycin is an antibacterial, mycoplasma, and chlamydia drug.
This time, it was found that it can resist the new crown.
Its mechanism is different from that of Azvudine, so we hope to have double insurance
.

Fever and cough are not necessarily caused by coronavirus, but other things, such as some interstitial pneumonia and mycoplasma, are very likely
.

Academician Jiang Jiandong said that there are many antiviral drugs now, such as Remdesivir, which has a good antiviral effect, but in the end, the new crown virus was not controlled
.
So, we hope that the drug Azvudine can be different
.

At present, part A of our plan has been completed, but the drug B has not been completed
.
After New Year's Day, Azivudin has been sent to foreign diplomatic envoys, officials stationed in Hong Kong, etc.
for trial use, with more than 10,000 copies.
So far, there is no report that contradicts the result
.

Regarding the safety of azvudine, we have obtained additional information: in the AIDS indication, the 3mg dose has been taken for 48 weeks, and there has been no death case.
The new crown indication is the dose of 5mg, and the dose has been increased, but still There were no serious side effects, ART increased and AST increased, up to 3 times (more than 100 levels), but after stopping the drug, it was normal, and the safety was good
.